Center for Molecular and Translational Medicine, Georgia State University, Atlanta (L.Q., C.Y., P.S., J.L., Y.D., M.H.Z.).
School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Guangzhou, China (Z. Xie, Z. Xu).
Circulation. 2022 Jun 14;145(24):1784-1798. doi: 10.1161/CIRCULATIONAHA.121.057868. Epub 2022 May 18.
IDO1 (indoleamine 2,3-dioxygenase 1) is the rate-limiting enzyme for tryptophan metabolism. IDO1 malfunction is involved in the pathogenesis of atherosclerosis. Vascular smooth muscle cells (VSMCs) with an osteogenic phenotype promote calcification and features of plaque instability. However, it remains unclear whether aberrant IDO1-regulated tryptophan metabolism causes VSMCs osteogenic reprogramming and calcification.
We generated global () and double knockout mice, and knockout mice with specific deletion of IDO1 in VSMCs or macrophages. Arterial intimal calcification was evaluated by a Western diet-induced atherosclerotic calcification model.
Global deficiency of IDO1 boosted calcific lesion formation without sex bias in vivo. Conditional IDO1 loss of function in VSMCs rather than macrophages promoted calcific lesion development and the abundance of RUNX2 (runt-related transcription factor 2). In contrast, administration of kynurenine via intraperitoneal injection markedly delayed the progression of intimal calcification in parallel with decreased RUNX2 expression in both and mice. We found that IDO1 deletion restrained RUNX2 from proteasomal degradation, which resulted in enhanced osteogenic reprogramming of VSMCs. Kynurenine administration downregulated RUNX2 in an aryl hydrocarbon receptor-dependent manner. Kynurenine acted as the endogenous ligand of aryl hydrocarbon receptor, controlled resultant interactions between cullin 4B and aryl hydrocarbon receptor to form an E3 ubiquitin ligase that bound with RUNX2, and subsequently promoted ubiquitin-mediated instability of RUNX2 in VSMCs. Serum samples from patients with coronary artery calcification had impaired IDO1 activity and decreased kynurenine catabolites compared with those without calcification.
Kynurenine, an IDO1-mediated tryptophan metabolism main product, promotes RUNX2 ubiquitination and subsequently leads to its proteasomal degradation via an aryl hydrocarbon receptor-dependent nongenomic pathway. Insufficient kynurenine exerts the deleterious role of IDO1 ablation in promoting RUNX2-mediated VSMCs osteogenic reprogramming and calcification in vivo.
IDO1(吲哚胺 2,3-双加氧酶 1)是色氨酸代谢的限速酶。IDO1 功能障碍与动脉粥样硬化的发病机制有关。具有成骨表型的血管平滑肌细胞(VSMCs)促进钙化和斑块不稳定的特征。然而,尚不清楚异常 IDO1 调节的色氨酸代谢是否导致 VSMCs 成骨重编程和钙化。
我们生成了全局()和双重敲除小鼠,以及在 VSMCs 或巨噬细胞中特异性缺失 IDO1 的 敲除小鼠。通过西方饮食诱导的动脉粥样硬化钙化模型评估动脉内膜钙化。
IDO1 的全局缺乏在体内没有性别偏见地促进了钙化病变的形成。VSMCs 而非巨噬细胞中 IDO1 功能丧失条件性促进了钙化病变的发展和 RUNX2( runt 相关转录因子 2)的丰度。相比之下,腹腔内注射犬尿氨酸显著延缓了 和 小鼠的内膜钙化进展,同时 RUNX2 的表达降低。我们发现 IDO1 缺失阻止了 RUNX2 的蛋白酶体降解,从而增强了 VSMCs 的成骨重编程。犬尿氨酸以芳香烃受体依赖的方式下调 RUNX2。犬尿氨酸作为芳香烃受体的内源性配体,控制 cullin 4B 和芳香烃受体之间的相互作用,形成 E3 泛素连接酶与 RUNX2 结合,随后促进 VSMCs 中 RUNX2 的泛素介导不稳定性。与无钙化的患者相比,伴有冠状动脉钙化的患者的血清样本中 IDO1 活性受损,犬尿氨酸代谢产物减少。
犬尿氨酸是 IDO1 介导的色氨酸代谢的主要产物,通过芳香烃受体依赖性非基因组途径促进 RUNX2 的泛素化,随后导致其蛋白酶体降解。体内,不足的犬尿氨酸发挥了 IDO1 缺失促进 RUNX2 介导的 VSMCs 成骨重编程和钙化的有害作用。